In Praise of Drug Megafunds

Researchers in the financial engineering lab at M.I.T. think they've struck on a solution that would allow investors to lower their risk, access new capital sources, and create more diverse portfolios while also giving a major shot in the arm to early-stage drug development.

North AmericaUS